Pliant Therapeutics, Inc.
pliantrx.comWhat Do They Do?
Develops integrin-based drug candidates and drug-delivery programs, including an oral treatment for solid tumors and therapies designed to deliver drug payloads to selected tissues.
10-K for FY2025, filed Mar 11, 2026We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is…View ↗
Our wholly owned lead product candidate, PLN-101095, is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins in…View ↗
Since our founding, we have built a drug discovery platform that today consists of a proprietary library of over 15,000 integrin binding…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$22.4MView ↗
- ▼ −48% (Loss)
- vs −$43.3M in Q2 FY2025
From fibrosis to oncology
The earlier report centered the business on fibrosis candidates for lung and liver disease, including bexotegrast. The latest report centers its lead program on a solid-tumor candidate and describes drug delivery and a broader integrin platform.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 11, 2026We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is…View ↗
Our wholly owned lead product candidate, PLN-101095, is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins in…View ↗
Since our founding, we have built a drug discovery platform that today consists of a proprietary library of over 15,000 integrin binding…View ↗
Who Do They Compete With?
Competes with AbbVie, Bicara Therapeutics, CatalyM, Corbus Pharmaceuticals, Incyte, IO Biotech, Keros Therapeutics, Oncotelic Therapeutics, Pfizer, Roche/Genetech, Scholar Rock, and Sirnaomics
10-K for FY2025, filed Mar 11, 2026Companies that compete with us directly on the level of commercialization or development of product candidates targeting various parts of…View ↗
Loading...
